SCHEMBL5160957

SCHEMBL5160957

COC(=O)CC(=O)c1cc2ccccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.59
KDM4E B2RXH2 3/20 0.58
ALDH1A1 P00352 1/20 0.58
GAA P10253 1/20 0.58
MAPK1 P28482 1/20 0.58
FLT3 P36888 4/20 0.57
MAPT P10636 1/20 0.56
DAO P14920 1/20 0.56
HPGD P15428 1/20 0.56
SRD5A2 P31213 1/20 0.56
HSD17B10 Q99714 1/20 0.56
LMNA P02545 2/20 0.54
TP53 P04637 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
PDGFRB P09619 5/20 0.54
PDGFRA P16234 5/20 0.54
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
DRD2 P14416 2/20 0.52
DRD3 P35462 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161463 0.87 IDO1 (0.55) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL5159785 0.85 IDO1 (0.54) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL5160302 0.85 KDM4E (0.68) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL7185518 0.85 IDO1 (0.56) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL9666519 0.84 IDO1 (0.62) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL30411827 0.83 IDO1 (0.60) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL5164244 0.81 IDO1 (0.59) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL5164287 0.81 KDM4E (0.71) IDO1KDM4EALDH1A1GAAMAPK1
SCHEMBL7087439 0.81 DRD2 (0.63) KDM4EALDH1A1GAAMAPK1HSD17B10
SCHEMBL519591 0.80 KDM4E (0.69) KDM4EALDH1A1GAAMAPK1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO IDO1 854/4885KDM4E 862/4885ALDH1A1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.